T. Rowe Price Associates
VIRX

T. Rowe Price Associates’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

T. Rowe Price Associates’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-81,136
Closed -$296K – 3026
2021
Q4 		$296K Sell
81,136
-987,676
-92% -$5.27M ﹤0.01% 2597
2021
Q3 		$8.57M Buy
+1,068,812
New +$10.5M ﹤0.01% 1439
2021
Q2 		– Sell
-510,000
Closed -$4.72M – 2959
2021
Q1 		$4.72M Buy
+510,000
New +$5.31M ﹤0.01% 1480
2015
Q3 		– Sell
-23,532
Closed -$14.9M – 2547
2015
Q2 		$14.9M Sell
23,532
-2,162
-8% -$1.15M ﹤0.01% 1235
2015
Q1 		$13.2M Sell
25,694
-1,306
-5% -$659K ﹤0.01% 1254
2014
Q4 		$14.5M Sell
27,000
-2,693
-9% -$1.21M ﹤0.01% 1223
2014
Q3 		$44.5M Buy
29,693
+12,963
+77% +$18.8M 0.01% 870
2014
Q2 		$22.9M Buy
16,730
+60
+0.4% +$69.6K ﹤0.01% 1079
2014
Q1 		$23.1M Sell
16,670
-717
-4% -$834K 0.01% 1068
2013
Q4 		$17.3M Buy
17,387
+4
+0% +$4.14K ﹤0.01% 1135
2013
Q3 		$18.1M Buy
17,383
+9,545
+122% +$10.2M ﹤0.01% 1112
2013
Q2 		$8.57M Buy
+7,838
New +$8.73M ﹤0.01% 1295

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates's VIRX Position: Q1 2022 in Review

T. Rowe Price Associates sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2022, closing a stake of 81,136 shares — an estimated $296K sold.

T. Rowe Price Associates first reported a position in VIRX in Q2 2013 and held it in 12 quarters. The position peaked at $44.5M in Q3 2014. 69 funds tracked by Wall St. Rank hold VIRX as of Q1 2022.

  • T. Rowe Price Associates reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 81,136 Viracta Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $296K.
  • T. Rowe Price Associates first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 12 quarters.
  • T. Rowe Price Associates's Viracta Therapeutics, Inc. Common Stock position peaked at $44.5M in Q3 2014.
  • 69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2022.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.